@article{fdi:010083851,
  title = {{H}epatitis {B} in {S}enegal : a successful infant vaccination program but urgent need to scale up screening and treatment ({ANRS} 12356 {A}m{BASS} survey)},
  author = {{P}{\'e}ri{\`e}res, {L}auren and {D}iallo, {A}. and {M}arcellin, {F}. and {N}ishimwe, {M}. {L}. and {B}a, {E}. and {C}oste, {M}. and {L}o, {G}. and {H}alfon, {P}. and {K}ane, {C}. {T}. and {M}aradan, {G}. and {C}arrieri, {P}. and {D}iouf, {A}. and {S}himakawa, {Y}. and {S}okhna, {C}heikh and {B}oyer, {S}. and {ANRS} 12356 {A}m{BASS} {S}urvey {S}tudy {G}roup},
  editor = {},
  language = {{ENG}},
  abstract = {{S}enegal introduced the infant hepatitis {B} virus ({HBV}) vaccination in 2004 and recently committed to eliminating hepatitis {B} by 2030. {U}pdated epidemiological data are needed to provide information on the progress being made and to develop new interventions. {W}e estimated the prevalence of hepatitis {B} surface antigen ({HB}s{A}g) in children and adults living in rural {S}enegal and assessed hepatitis {B} treatment eligibility. {A} cross-sectional population-based serosurvey of {HB}s{A}g was conducted in 2018-2019 in a large sample (n = 3,118) of residents living in the {N}iakhar area ({F}atick region, {S}enegal). {I}ndividuals positive for {HB}s{A}g subsequently underwent clinical and biological assessments. {D}ata were weighted for age and sex and calibrated to be representative of the area's population. {A}mong the 3,118 participants, 206 were {HB}s{A}g positive (prevalence, 6.9%; 95% confidence interval [{CI}], 5.6-8.1). {P}revalence varied markedly according to age group in individuals aged 0-4, 5-14, 15-34, and >= 35 years as follows: 0.0% (95% {CI}, 0.00-0.01); 1.5% (95% {CI}, 0.0-2.3); 12.4% (95% {CI}, 9.1-15.6); and 8.8% (95% {CI}, 6.1-11.5), respectively. {O}f those subsequently assessed, 50.9% (95% {CI}, 41.8-60.0) had active {HBV} infection; 4 (2.9%; 95% {CI}, 0.9-9.4) were eligible for hepatitis {B} treatment. {C}onclusion: {I}n this first population-based serosurvey targeting children and adults in rural {S}enegal, {HB}s{A}g prevalence was very low in the former, meeting the {W}orld {H}ealth {O}rganization's ({WHO}) < 1% {HB}s{A}g 2020 target; however, it was high in young adults (15-34 years old) born before the {HBV} vaccine was introduced in 2004. {T}o reach national and {WHO} hepatitis elimination goals, general population testing (particularly for adolescents and young adults), care, and treatment scale-up need to be implemented.},
  keywords = {{SENEGAL}},
  booktitle = {},
  journal = {{H}epatology {C}ommunications},
  volume = {6},
  numero = {5},
  pages = {1005--1015},
  year = {2022},
  DOI = {10.1002/hep4.1879},
  URL = {https://www.documentation.ird.fr/hor/fdi:010083851},
}